Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND.

Repovic, Pavle; Robertson, Derrick; Kresa-Reahl, Kiren; Cohan, Stanley L; Su, Ray; Avila, Robin; Koulinska, Irene; Mendoza, Jason P

Repovic, Pavle; Robertson, Derrick; Kresa-Reahl, Kiren; Cohan, Stanley L; Su, Ray; Avila, Robin; Koulinska, Irene; Mendoza, Jason P.

Afiliação

Repovic P; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA.
Robertson D; Multiple Sclerosis Division, Department of Neurology, University of South Florida College of Medicine, Tampa, FL, USA.
Kresa-Reahl K; Providence Multiple Sclerosis Center, Portland, OR, USA.
Cohan SL; Providence Multiple Sclerosis Center, Portland, OR, USA.
Su R; Biogen, Cambridge, MA, USA.
Avila R; Biogen, Cambridge, MA, USA.
Koulinska I; Biogen, Cambridge, MA, USA.
Mendoza JP; Biogen, Cambridge, MA, USA. jason.mendoza@biogen.com.

Neurol Ther ; 10(1): 169-182, 2021 Jun.

Article em En | MEDLINE | ID: mdl-33225410

Palavras-chave

Annualized relapse rate; Dimethyl fumarate; Glatiramer acetate; Patient-reported outcomes; Relapsing multiple sclerosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article